Results 31 to 40 of about 89,205 (311)

ONS Omnibus Survey, October 2002

open access: yes, 2004
copyright UK Data Service and data collection copyright owner.The Opinions and Lifestyle Survey (formerly known as the ONS Opinions Survey or Omnibus) is an omnibus survey that began in 1990, collecting data on a range of subjects commissioned by both ...
Office for National Statistics, Social Survey Division
core   +1 more source

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm   +11 more
wiley   +1 more source

ONS Omnibus Survey, June 2000

open access: yes, 2002
copyright UK Data Service and data collection copyright owner.The Opinions and Lifestyle Survey (formerly known as the ONS Opinions Survey or Omnibus) is an omnibus survey that began in 1990, collecting data on a range of subjects commissioned by both ...
Office for National Statistics, Social Survey Division
core   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke   +4 more
wiley   +1 more source

ONS Omnibus Survey, October 2000

open access: yes, 2002
copyright UK Data Service and data collection copyright owner.The Opinions and Lifestyle Survey (formerly known as the ONS Opinions Survey or Omnibus) is an omnibus survey that began in 1990, collecting data on a range of subjects commissioned by both ...
Office for National Statistics, Social Survey Division
core   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook   +6 more
wiley   +1 more source

Ergebnisse einer Mitarbeiterbefragung bei der Lynx Consulting Group/Bielefeld [PDF]

open access: yes, 2000
Der vorliegende Bericht beschäftigt sich mit einer Mitarbeiterbefragung, die in den Monaten März und April 2000 bei der Lynx Consulting Group in Bielefeld durchgeführt und im Mai 2000 ausgewertet und präsentiert wurde.
Weller, Ingo, Steffen, Eckhard
core  

ONS Omnibus Survey, August 1996

open access: yes, 1999
copyright UK Data Service and data collection copyright owner.The Opinions and Lifestyle Survey (formerly known as the ONS Opinions Survey or Omnibus) is an omnibus survey that began in 1990, collecting data on a range of subjects commissioned by both ...
Office for National Statistics, Social Survey Division
core   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy